New slow‑release device clears bladder tumours in 82% of patients — a potential game changer for Thai patients who cannot or will not have their bladder removed
A novel intravesical drug‑releasing system called TAR‑200 eliminated visible bladder cancer in about 82% of patients with high‑risk non‑muscle‑invasive bladder cancer (NMIBC) who had failed standard Bacillus Calmette‑Guérin (BCG) therapy, according to data from the phase 2b SunRISe‑1 study that could fast‑track regulatory review in the United States. The device slowly releases the chemotherapy drug gemcitabine inside the bladder over three weeks, offering a bladder‑sparing alternative to radical cystectomy for patients at high risk of progression (Keck Medicine report) (Johnson & Johnson press release).